Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,695 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hourly Air Pollutants and Acute Coronary Syndrome Onset in 1.29 Million Patients.
Chen R, Jiang Y, Hu J, Chen H, Li H, Meng X, Ji JS, Gao Y, Wang W, Liu C, Fang W, Yan H, Chen J, Wang W, Xiang D, Su X, Yu B, Wang Y, Xu Y, Wang L, Li C, Chen Y, Bell ML, Cohen AJ, Ge J, Huo Y, Kan H. Chen R, et al. Among authors: su x. Circulation. 2022 Jun 14;145(24):1749-1760. doi: 10.1161/CIRCULATIONAHA.121.057179. Epub 2022 Apr 22. Circulation. 2022. PMID: 35450432
Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial.
Gao R, Yang Y, Han Y, Huo Y, Chen J, Yu B, Su X, Li L, Kuo HC, Ying SW, Cheong WF, Zhang Y, Su X, Xu B, Popma JJ, Stone GW; ABSORB China Investigators. Gao R, et al. Among authors: su x. J Am Coll Cardiol. 2015 Dec 1;66(21):2298-2309. doi: 10.1016/j.jacc.2015.09.054. Epub 2015 Oct 12. J Am Coll Cardiol. 2015. PMID: 26471805 Free article. Clinical Trial.
Efficacy and Safety of a Pharmaco-Invasive Strategy With Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment-Elevation Myocardial Infarction: EARLY-MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction).
Pu J, Ding S, Ge H, Han Y, Guo J, Lin R, Su X, Zhang H, Chen L, He B; EARLY-MYO Investigators. Pu J, et al. Among authors: su x. Circulation. 2017 Oct 17;136(16):1462-1473. doi: 10.1161/CIRCULATIONAHA.117.030582. Epub 2017 Aug 27. Circulation. 2017. PMID: 28844990 Clinical Trial.
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
Holman RR, Coleman RL, Chan JCN, Chiasson JL, Feng H, Ge J, Gerstein HC, Gray R, Huo Y, Lang Z, McMurray JJ, Rydén L, Schröder S, Sun Y, Theodorakis MJ, Tendera M, Tucker L, Tuomilehto J, Wei Y, Yang W, Wang D, Hu D, Pan C; ACE Study Group. Holman RR, et al. Lancet Diabetes Endocrinol. 2017 Nov;5(11):877-886. doi: 10.1016/S2213-8587(17)30309-1. Epub 2017 Sep 13. Lancet Diabetes Endocrinol. 2017. PMID: 28917545 Clinical Trial.
Safety and efficacy of zotarolimus-eluting stents in the treatment of diabetic coronary lesions in Chinese patients: The RESOLUTE-DIABETES CHINA Study.
Zhu Z, Wu Y, Shen Z, Xu Y, Li Y, Wang Y, Su X, Li B, Jiang T, Jiang J, Wang L, He S, Li X, Li H, Liu Y, Zhou Y, Tang Q, Chen Y, Fang W, Jiang L, Lu C, Guo J, Zhang J, Chen S, Xia Y, Zheng H, Wang B, Zhang D, Feng L, Tang L, Xu P, Liu X, Zhang R; RESOLUTE-DIABETES CHINA Investigators. Zhu Z, et al. Among authors: su x. J Diabetes. 2019 Mar;11(3):204-213. doi: 10.1111/1753-0407.12832. Epub 2018 Sep 7. J Diabetes. 2019. PMID: 30070032
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Schwartz GG, et al. N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7. N Engl J Med. 2018. PMID: 30403574 Free article. Clinical Trial.
Safety and efficacy of the novel sirolimus-eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: One-year results from a prospective patient-level pooled analysis of NeoVas trials.
Xu K, Fu G, Xu B, Zhou Y, Su X, Liu H, Zhang Z, Yu B, Wang X, Han Y; NeoVas OPC Investigators. Xu K, et al. Among authors: su x. Catheter Cardiovasc Interv. 2019 Feb 15;93(S1):832-838. doi: 10.1002/ccd.28067. Catheter Cardiovasc Interv. 2019. PMID: 30888736
A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS study.
Chen Y, Yin T, Xi S, Zhang S, Yan H, Tang Y, Qian J, Chen J, Su X, Du Z, Wang L, Qin Q, Gao C, Zheng Y, Zhao X, Cheng X, Li Z, Zhang W, Chen H, Wang J, Yang Z, Li H, Liu H, Zhou X, Qu B, Xiang D, Guo Y, Wang L, Nie S, Fu G, Yang M, Cai S. Chen Y, et al. Among authors: su x. Catheter Cardiovasc Interv. 2019 Jun 1;93(7):1194-1204. doi: 10.1002/ccd.28325. Epub 2019 May 21. Catheter Cardiovasc Interv. 2019. PMID: 31112635
9,695 results